

Joana Torres

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8567650/publications.pdf>

Version: 2024-02-01

67
papers

3,985
citations

270111

25
h-index

169272

56
g-index

69
all docs

69
docs citations

69
times ranked

5640
citing authors

#	ARTICLE	IF	CITATIONS
1	Histological Inflammation in the Endoscopically Uninflamed Mucosa is Associated With Worse Outcomes in Limited Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 350-357.	0.9	4
2	Is Prevention the Best Way to Modify Inflammatory Bowel Disease? How Close Are We?. <i>Gastroenterology</i> , 2022, 162, 1452-1455.	0.6	7
3	Breastfeeding Is Associated with Lower Likelihood of Helicobacter Pylori Colonization in Babies, Based on a Prospective USA Maternal-Infant Cohort. <i>Digestive Diseases and Sciences</i> , 2022, , 1.	1.1	4
4	Probing the Microbiome to Predict Response to Biologic Therapy in Inflammatory Bowel Disease—One Step Closer to Precision Medicine?. <i>Gastroenterology</i> , 2022, , .	0.6	0
5	Neutralizing Anti-Granulocyte Macrophage-Colony Stimulating Factor Autoantibodies Recognize Post-Translational Glycosylations on Granulocyte Macrophage-Colony Stimulating Factor Years Before Diagnosis and Predict Complicated Crohn's Disease. <i>Gastroenterology</i> , 2022, 163, 659-670.	0.6	18
6	Mode of Delivery Does Not Affect the Risk of Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 398-407.	1.1	8
7	Point-of-Care Intestinal Ultrasound Examination: Prime Time for the Management of Ulcerative Colitis?. <i>Gastroenterology</i> , 2021, 160, 964-965.	0.6	3
8	Longitudinal Changes in Fecal Calprotectin Levels Among Pregnant Women With and Without Inflammatory Bowel Disease and Their Babies. <i>Gastroenterology</i> , 2021, 160, 1118-1130.e3.	0.6	41
9	Reply. <i>Gastroenterology</i> , 2021, 160, 476-477.	0.6	0
10	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD—Disease Outcome and Response to Therapy. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1431-1442.	0.6	39
11	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD—Prediction and Prevention of Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1443-1454.	0.6	33
12	Steering a Course through the COVID-19 Pandemic: Should the SECURE-IBD Registry Influence Prescribing for Patients with Inflammatory Bowel Disease?. <i>Gastroenterology</i> , 2021, 160, 1867-1870.	0.6	2
13	DOP61 Impact of prior tumour necrosis factor inhibitor failure and prior corticosteroid use on the maintenance of efficacy of tofacitinib following dose reduction in patients with Ulcerative Colitis who were in stable remission: 6-month data from the double-blind, randomised RIVETING study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S096-S097.	0.6	0
14	P065 Conservation of breast milk cytokine profiles in consecutive pregnancies of women with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S170-S171.	0.6	0
15	P048 Intestinal inflammation and microbiome diversity are conserved more in consecutive pregnancies among women with inflammatory bowel disease compared to healthy controls. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S156-S158.	0.6	0
16	P409 Non-invasive predictors of maintaining remission in patients with moderately to severely active Ulcerative Colitis treated with tofacitinib who dose-reduced from tofacitinib 10 mg twice daily to 5 mg twice daily: 6-month data from the double-blind, randomised RIVETING study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S416-S417.	0.6	0
17	P336 Association between the prior duration of remission and efficacy outcomes in patients with Ulcerative Colitis treated with tofacitinib 10 mg twice daily who were in stable remission and either dose-reduced to tofacitinib 5 mg twice daily or remained on 10 mg twice daily: 6-month data from the double-blind, randomised RIVETING study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S361-S362.	0.6	0
18	Early life exposures and the risk of inflammatory bowel disease: Systematic review and meta-analyses. <i>EclinicalMedicine</i> , 2021, 36, 100884.	3.2	47

#	ARTICLE	IF	CITATIONS
19	Early Life Greenspace and the Risk of Pediatric-Onset Inflammatory Bowel Disease: Insights into the Link Between Environmental and Human Health. <i>Gastroenterology</i> , 2021, 161, 355-357.	0.6	2
20	Selecting the Ideal Candidate for Anti-TNF Discontinuation in Crohn's Disease, Dream or Reality?. <i>Gastroenterology</i> , 2021, 161, 353-355.	0.6	1
21	Anti-SARS-CoV-2 Antibody Responses in Patients With IBD Treated With Biologics: Are We Finding CLARITY?. <i>Gastroenterology</i> , 2021, 161, 2057-2059.	0.6	2
22	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD—What, Why, and How. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1410-1430.	0.6	28
23	Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice. <i>Gut</i> , 2020, 69, 42-51.	6.1	121
24	Association Between Indefinite Dysplasia and Advanced Neoplasia in Patients With Inflammatory Bowel Diseases Undergoing Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1518-1527.e3.	2.4	26
25	Prediction of Inflammatory Bowel Disease: A Step Closer?. <i>Gastroenterology</i> , 2020, 158, 278-279.	0.6	7
26	Excellent Accuracy of Glucose Level in Cystic Fluid for Diagnosis of Pancreatic Mucinous Cysts. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2071-2078.	1.1	32
27	Preclinical disease and preventive strategies in IBD. <i>Current Opinion in Pharmacology</i> , 2020, 55, 110-115.	1.7	2
28	P030 Dynamics of intestinal inflammation and microbial dysbiosis in pregnant women with IBD and their infants. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S146-S147.	0.6	1
29	400 GM-CSF AUTOANTIBODIES PRECEDE THE DEVELOPMENT OF CROHN'S DISEASE AND PREDICT COMPLICATED PHENOTYPE AT DIAGNOSIS. <i>Gastroenterology</i> , 2020, 158, S-74.	0.6	4
30	Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3533.	1.0	29
31	Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis. <i>Gastroenterology</i> , 2020, 159, 96-104.	0.6	129
32	A dietary intervention to improve the microbiome composition of pregnant women with Crohn's disease and their offspring: The MELODY (Modulating Early Life Microbiome through Dietary) Trial. <i>Overlock 10, 11, 50, 222, 100573.</i>	0.5	24
33	Evaluation of ileal Crohn's disease response to TNF antagonists: Validation of MR enterography for assessing response. Initial results. <i>European Journal of Radiology Open</i> , 2020, 7, 100217.	0.7	9
34	Association Between Early-life Exposures and Inflammatory Bowel Diseases, Based on Analyses of Deciduous Teeth. <i>Gastroenterology</i> , 2020, 159, 383-385.	0.6	14
35	You Are What You Eat, But Can Diet Prevent Inflammatory Bowel Diseases?. <i>Gastroenterology</i> , 2020, 158, 2304-2305.	0.6	2
36	Editorial: Gastrointestinal 2020: Novel inflammatory bowel disease treatments and therapeutic drug monitoring. <i>Current Opinion in Pharmacology</i> , 2020, 55, iii-vi.	1.7	0

#	ARTICLE	IF	CITATIONS
37	Controversies in Inflammatory Bowel Disease: Exploring Clinical Dilemmas Using Cochrane Reviews. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 472-478.	0.9	1
38	Neonatal Life Events and the Risk of Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2019, 157, 1440-1441.	0.6	1
39	DOP35 Innate immune dysregulation, detectable up to 6 years before the diagnosis of Crohn's disease, is significantly amplified in patients with a complicated phenotype. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S045-S046.	0.6	0
40	Cohort profile of the PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects (PREDICTS) study: Rationale, organization, design, and baseline characteristics. <i>Contemporary Clinical Trials Communications</i> , 2019, 14, 100345.	0.5	24
41	No Association Between Pseudopolyps and Colorectal Neoplasia in Patients With Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2019, 156, 1333-1344.e3.	0.6	58
42	Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis: results of a 15-year multicentre, multinational cohort study. <i>Gut</i> , 2019, 68, 615-622.	6.1	27
43	Statin Exposure Is Not Associated with Reduced Prevalence of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease. <i>Gut and Liver</i> , 2019, 13, 54-61.	1.4	16
44	Primary Sclerosing Cholangitis Overlapping with IBD. , 2019, , 191-204.		0
45	Bariatric surgery is associated with increased risk of new-onset inflammatory bowel disease: case series and national database study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1126-1134.	1.9	26
46	Farnesoid X Receptor Expression in Microscopic Colitis: A Potential Role in Disease Etiopathogenesis. <i>GE Portuguese Journal of Gastroenterology</i> , 2018, 25, 30-37.	0.3	9
47	Editorial: the role of colonic inflammation in the progression of liver disease in patients with primary sclerosing cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 439-440.	1.9	2
48	Magnetic Resonance Imaging Predicts Histopathological Composition of Ileal Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 718-729.	0.6	45
49	High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1106-1113.e3.	2.4	74
50	Luminally polarized mural and vascular remodeling in ileal strictures of Crohn's disease. <i>Human Pathology</i> , 2018, 79, 42-49.	1.1	16
51	Adherent-invasive <i>Escherichia coli</i> in inflammatory bowel disease. <i>Gut</i> , 2018, 67, 574-587.	6.1	366
52	Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features. <i>Gut and Liver</i> , 2018, 12, 17-29.	1.4	106
53	P160 Faecal Lactoferrin is a reliable IBD biomarker during pregnancy. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S178-S178.	0.6	3
54	Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1481-1492.	1.9	55

#	ARTICLE	IF	CITATIONS
55	Crohn's disease. <i>Lancet, The</i> , 2017, 389, 1741-1755.	6.3	1,594
56	The features of mucosa-associated microbiota in primary sclerosing cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 790-801.	1.9	112
57	Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities. <i>Gut</i> , 2016, 65, 1061-1069.	6.1	68
58	Serologic microbial associated markers can predict Crohn's disease behaviour years before disease diagnosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1300-1310.	1.9	105
59	Autoimmune pancreatitis and inflammatory bowel disease: Case series and review of the literature. <i>Digestive and Liver Disease</i> , 2016, 48, 893-898.	0.4	18
60	Evidence for Life Before Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 825-828.	2.4	6
61	Genetics and phenotypes in inflammatory bowel disease. <i>Lancet, The</i> , 2016, 387, 98-100.	6.3	35
62	Review article: non-malignant oral manifestations in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 40-60.	1.9	55
63	Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2015, 149, 1716-1730.	0.6	180
64	Evaluating Disability in Inflammatory Bowel Diseases: A Step Forward for Improved Care. <i>GE Portuguese Journal of Gastroenterology</i> , 2015, 22, 2-3.	0.3	0
65	Farnesoid X Receptor Expression Is Decreased in Colonic Mucosa of Patients with Primary Sclerosing Cholangitis and Colitis-associated Neoplasia. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 275-282.	0.9	38
66	Ulcerative Colitis as A Progressive Disease: The Forgotten Evidence. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1356-1363.	0.9	207
67	Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 497-508.	1.9	98